Table 1.

Effect of huRANKL treatment of C4-2 cells on bone morphometry

	BV/TV (%)	TuV/TV (%)	Tb.Th. (μm)	Tb.N. (mm-1)	Tb.Sp. (μm)	Ob.Pm./B.Pm. (%)	N.Oc./BS (#/mm)
Control	5.88 ± 0.99	80.48 ± 2.49	31.58 ± 4.83	2.03 ± 0.42	597.24 ± 215.70	5.23 ± 1.03	4.06 ± 0.37
Prevention	6.65 ± 2.31	78.69 ± 2.06	34.27 ± 2.05	1.84 ± 0.50	690.77 ± 188.80	9.51 ± 1.76a	4.37 ± 0.71
Treatment	6.75 ± 1.72	77.85 ± 2.99	36.00 ± 4.80	1.79 ± 0.37	633.46 ± 193.00	8.35 ± 2.66	6.32 ± 0.50b

Bone histomorphometric analysis was performed in the area adjacent to the growth plate (0.525–1.225 mm below the growth plate: site of injection, n = 4 in control and treatment animals; n = 5 in prevention animals. Two animals were removed from the analysis due to sectioning difficulties. Results are expressed as mean ± SE. Statistical significance was evaluated using student's paired t test. ^a Control vs. prevention (p < 0.05). ^b Control vs. treatment (p < 0.05). Abbreviations: %BV/TV, percentage bone volume in tissue volume; %TuV/TV, tumor volume in tissue volume as a percentage; Tb.Th., trabecular thickness in μm; Tb.N., trabecular number per mm; Tb.Sp., trabecular seperation in μm; Ob.Pm./B.Pm., osteoblast perimeter to bone perimeter; N.Oc./BS, ratio of osteoclast number to bone surface.